We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
301
CALL
Tvardi Therapeutics
TVRD
$19.7M
– –
-23,517
Closed -$18.4M
CMRX
302
CALL
DELISTED
Chimerix, Inc.
CMRX
– –
-150,000
Closed -$1.45M
ITCI
303
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-75,000
Closed -$2.54M
SYRS
304
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-10,000
Closed -$748K
VIRX
305
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-155,599
Closed -$1.44M
MORF
306
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-49,925
Closed -$3.16M
KNTE
307
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-2,000
Closed -$62K
SNCE
308
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-25,623
Closed -$5.2M
NVTA
309
PUT
DELISTED
Invitae Corporation
NVTA
– –
-200,000
Closed -$7.64M
MRTX
310
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-94,500
Closed -$16.2M
MRTX
311
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-162,000
Closed -$27.8M
ICPT
312
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-100,000
Closed -$2.31M
RETA
313
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-600
Closed -$67.8K
TCRR
314
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-136,486
Closed -$3.01M
RUBY
315
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-50,000
Closed -$1.33M
ALBO
316
DELISTED
Albireo Pharma Inc
ALBO
– –
-16,883
Closed -$595K
SRNE
317
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-165,900
Closed -$1.37M
ARNA
318
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-2,200
Closed -$143K
SBBP
319
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-1,160,450
Closed -$3.2M
TBIO
320
PUT
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-250,000
Closed -$4.12M
GWPH
321
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-119,100
Closed -$25.8M
CEMI
322
DELISTED
Chembio diagnostics, Inc.
CEMI
– –
-219,109
Closed -$769K
9 10 11 12
13

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.